Hospitals

Parathon Names Steven Golub Chief Technology Officer

Industry veteran brings more than two decades of experience leading technology initiatives   NAPERVILLE, Ill., July 9, 2024 /PRNewswire/ --…

9 months ago

Raphael Pharmaceutical Issues Letter to Shareholders

Highlights Company’s exclusive relationship with Rambam Health Care Campus, differentiated cannabinoid-based technology platform, promising lead product candidate for rheumatoid arthritis,…

9 months ago

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

JV will Establish Company’s 4th International CenterSAN FRANCISCO, July 09, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…

9 months ago

Tilray Medical Announces Scientific Study on Medical Cannabis for Patients Over Age 50

Older Patients Represent a Rapidly Growing Subset for Therapeutic Medical Cannabis Use for Pain, Sleep, Quality of Life and Co-MedicationBERLIN,…

9 months ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients…

9 months ago

Best Rated San Antonio Plastic Surgeons for 2024 (Q1) Research Report Released by Doctor Marketing, MD

The Review Growth Index™ (RGI™) by Doctor Marketing, MD™ releases the researched list of Top Rated Plastic Surgery Practices in…

9 months ago

GE HealthCare to announce second quarter 2024 results on July 31, 2024

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second…

9 months ago

GE HealthCare to announce second quarter 2024 results on July 31, 2024

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, will announce its second…

9 months ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct…

9 months ago

Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…

9 months ago